Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Markopoulos

Showing results (81-90 of 89) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 89 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 19, 2006
Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology GroupH Gogas, A Polyzos, I Stavrinidis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 7, 2002
Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology GroupH Gogas, C Papadimitriou, H P Kalofonos, et al.
British Journal of Cancer|October 15, 2014
Time dependence of biomarkers: non-proportional effects of immunohistochemical panels predicting relapse risk in early breast cancerJ Stephen, G Murray, D A Cameron, et al.
European Journal of Cancer (Oxford, England : 1990)|June 10, 2018
Impact of age on breast cancer mortality and competing causes of death at 10 years follow-up in the adjuvant TEAM trialM G M Derks, E Bastiaannet, W van de Water, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 9, 2005
Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology GroupG Fountzilas, D Skarlos, U Dafni, et al.
British Journal of Cancer|October 5, 2013
Do type 1 receptor tyrosine kinases inform treatment choice? A prospectively planned analysis of the TEAM trialJ M S Bartlett, C L Brookes, T Piper, et al.
The British Journal of Surgery|April 16, 2010
Variations in locoregional therapy in postmenopausal patients with early breast cancer treated in different countriesJ G H van Nes, C Seynaeve, S Jones, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 29, 2007
Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00G Fountzilas, U Dafni, H Gogas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2015
Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European PanelP Hadji, R E Coleman, C Wilson, et al.
Pageof 9

Showing results (81-90 of 89) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 89 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 19, 2006
Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology GroupH Gogas, A Polyzos, I Stavrinidis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 7, 2002
Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology GroupH Gogas, C Papadimitriou, H P Kalofonos, et al.
British Journal of Cancer|October 15, 2014
Time dependence of biomarkers: non-proportional effects of immunohistochemical panels predicting relapse risk in early breast cancerJ Stephen, G Murray, D A Cameron, et al.
European Journal of Cancer (Oxford, England : 1990)|June 10, 2018
Impact of age on breast cancer mortality and competing causes of death at 10 years follow-up in the adjuvant TEAM trialM G M Derks, E Bastiaannet, W van de Water, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 9, 2005
Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology GroupG Fountzilas, D Skarlos, U Dafni, et al.
British Journal of Cancer|October 5, 2013
Do type 1 receptor tyrosine kinases inform treatment choice? A prospectively planned analysis of the TEAM trialJ M S Bartlett, C L Brookes, T Piper, et al.
The British Journal of Surgery|April 16, 2010
Variations in locoregional therapy in postmenopausal patients with early breast cancer treated in different countriesJ G H van Nes, C Seynaeve, S Jones, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 29, 2007
Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00G Fountzilas, U Dafni, H Gogas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2015
Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European PanelP Hadji, R E Coleman, C Wilson, et al.
Pageof 9